Ultragenyx Pharmaceutical is rated a soft Buy with a current share price near $27 and a probability-weighted fair value of about $32 per share. The company faces two near-term FDA decisions: one on gene therapy DTX401 for glycogen storage disease type Ia on August 23, and another on UX111 on September 19. DTX401 has a stronger regulatory case with an 80% approval chance, while UX111 has a 65% chance. Ultragenyx expects significant revenue from existing products by 2026, and the market currently undervalues the probability of at least one drug approval. Risks include manufacturing issues and financing needs, but the upcoming FDA decisions are key catalysts for the stock.
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
TOMI Environmental Solutions reported a 118% year-over-year revenue increase to $2.25 million, surpassing analyst estimates of $1.84 million. The company also beat EPS expectations with a loss of $0.05 per share, better than the anticipated loss of $...
Seaport Global raised the price target for Madison Square Garden Sports Corp. to $473, reflecting a 17.13% potential upside. The company reported strong fiscal Q4 results with earnings per share of $1.19, beating estimates of $0.72, and revenue risin...
Airbus is outperforming Boeing in commercial aircraft orders, securing 821 net orders in H1 2026 compared to Boeing's 408. Morgan Stanley maintains an "Overweight" rating on Airbus, raising its price target to €255, reflecting confidence in the compa...
PAVmed reported a Q2 2026 GAAP loss per share of $0.87 and a non-GAAP loss of $0.27, beating analyst expectations of a $0.47 loss. Revenue was $33,000, below the $49,000 consensus. Lucid Diagnostics, an investment of PAVmed, generated $1.5 million in...
